2023
Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions
Zubair A, Rethana M, Ma A, McAlpine L, Abulaban A, Munro B, Patwa H, Nowak R, Roy B. Plasmapheresis Versus Intravenous Immunoglobulin in Patients With Autoimmune Neuromuscular and Neuro-immunological Conditions. Journal Of Clinical Neuromuscular Disease 2023, 25: 11-17. PMID: 37611265, DOI: 10.1097/cnd.0000000000000439.Peer-Reviewed Original ResearchConceptsNeuro-immunological diseaseIntravenous immunoglobulinAutoimmune neurological disordersAutoimmune neuromuscular disorderAdult patientsElderly patientsNeurological disordersNeuromuscular disordersChronic inflammatory demyelinating polyradiculoneuropathyNational Inpatient Sample databaseNational Inpatient Sample datasetInflammatory demyelinating polyradiculoneuropathySafe therapeutic choiceRetrospective chart reviewAppropriate clinical settingSide effect profileDemyelinating polyradiculoneuropathyIVIG useChart reviewYounger patientsMyasthenia gravisEffect profileMedical historyPrimary diagnosisTherapeutic choice
2019
P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin
Genge A, Jacob S, Murai H, Utsugisawa K, Nowak R, Wiendl H, Fujita K, O’Brien F, Howard J. P.026 Response to eculizumab in patients with myasthenia gravis recently treated with chronic intravenous immunoglobulin. Canadian Journal Of Neurological Sciences / Journal Canadien Des Sciences Neurologiques 2019, 46: s20-s21. DOI: 10.1017/cjn.2019.126.Peer-Reviewed Original ResearchIntravenous immunoglobulinMyasthenia gravisAnti-acetylcholine receptor antibody-positive refractoryRefractory myasthenia gravisOpen-label extensionPlacebo-controlled studyMeaningful clinical improvementExperienced exacerbationRescue therapyClinical improvementEighteen patientsMore patientsSubgroup analysisEculizumabPatientsPlaceboExacerbationRelevant improvementGravisPhase 3Status changesInterim dataImmunoglobulinPrevious reportsMeaningful responses